TY - JOUR

T1 - The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions

AU - Alrhmoun, Saleh

AU - Sennikov, Sergey

N1 - This research was funded by Russian Science Foundation—RSF, No 21-65-00004, https://rscf.ru/en/project/21-65-00004/

PY - 2022/12/14

Y1 - 2022/12/14

N2 - The treatment of HER2-positive cancers has changed significantly over the past ten years thanks to a significant number of promising new approaches that have been added to our arsenal in the fight against cancer, including monoclonal antibodies, inhibitors of tyrosine kinase, antibody-drug conjugates, vaccination, and particularly, adoptive-T-cell therapy after its great success in hematological malignancies. Equally important is the new methodology for determining patients eligible for targeted HER2 therapy, which has doubled the number of patients who can benefit from these treatments. However, despite the initial enthusiasm, there are still several problems in this field represented by drug resistance and tumor recurrence that require the further development of new more efficient drugs. In this review, we discuss various approaches for targeting the HER2 molecule in cancer treatment, highlighting their benefits and drawbacks, along with the different mechanisms responsible for resistance to HER2-targeted therapies and how to overcome them.

AB - The treatment of HER2-positive cancers has changed significantly over the past ten years thanks to a significant number of promising new approaches that have been added to our arsenal in the fight against cancer, including monoclonal antibodies, inhibitors of tyrosine kinase, antibody-drug conjugates, vaccination, and particularly, adoptive-T-cell therapy after its great success in hematological malignancies. Equally important is the new methodology for determining patients eligible for targeted HER2 therapy, which has doubled the number of patients who can benefit from these treatments. However, despite the initial enthusiasm, there are still several problems in this field represented by drug resistance and tumor recurrence that require the further development of new more efficient drugs. In this review, we discuss various approaches for targeting the HER2 molecule in cancer treatment, highlighting their benefits and drawbacks, along with the different mechanisms responsible for resistance to HER2-targeted therapies and how to overcome them.

KW - CAR-T cells

KW - HER2

KW - HER2-positive cancer

KW - HER2-targeted immunotherapy

KW - HER2-targeted vaccines

KW - antibody–drug conjugates

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85145004999&origin=inward&txGid=7b740cb5c9f9d85210d129e80de060df

UR - https://www.mendeley.com/catalogue/4f05e426-a50b-3ead-aee5-21f149d08513/

U2 - 10.3390/cancers14246173

DO - 10.3390/cancers14246173

M3 - Review article

C2 - 36551661

VL - 14

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 24

M1 - 6173

ER -